Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518127

— · D

b87256cf-0012-578b-bc85-3fe7461dbabf

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.590
  • INTERFERON_GAMMA_RESPONSE+0.590
  • INTERFERON_ALPHA_RESPONSE+0.560
  • IL6_JAK_STAT3_SIGNALING+0.530
  • INFLAMMATORY_RESPONSE+0.530
  • COMPLEMENT+0.480
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
  • IL2_STAT5_SIGNALING+0.400
  • COAGULATION+0.350
  • KRAS_SIGNALING_UP+0.350

Top 10 suppressed

  • CHOLESTEROL_HOMEOSTASIS-0.340
  • PROTEIN_SECRETION-0.320
  • MYC_TARGETS_V1-0.310
  • OXIDATIVE_PHOSPHORYLATION-0.290
  • ESTROGEN_RESPONSE_EARLY-0.260
  • TGF_BETA_SIGNALING-0.250
  • ADIPOGENESIS-0.220
  • NOTCH_SIGNALING-0.220
  • ANDROGEN_RESPONSE-0.210
  • DNA_REPAIR-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BH-A0BF-01A-21R-A12P-07
breast-umap@18
—D0.897
2X038167c2.c7d9.47a2.9172.1cfe391c8131
lung-landscapes@6
—cohortMD20.875
3TCGA-FD-A5BS-01A-21R-A26T-07
bladder-landscape@3
——0.869
4SRR8518332
breast-umap@18
—D0.868
5C3L-03976
lung-landscapes@6
—cohortMD20.865
6TCGA-55-8208-01A-11R-2241-07
lung-landscapes@6
—cohortMD20.863
7BS_JBGZ7HHZ
brain-umap@2
ganglioneuroblastoma—0.861
8DRR168577
bladder-landscape@3
——0.853
9MNG303
mng-umap@100
——0.847
100ec02d90-7ccb-476e-a8bb-9a9c8f158dee
melanoma-umap@29
——0.844

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.590Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.590Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.560Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.530Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.530Idelalisib— uncovered
COMPLEMENT0.480Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.430Inavolisib— uncovered
IL2_STAT5_SIGNALING0.400Idelalisib— uncovered
COAGULATION0.350Binimetinib— uncovered
KRAS_SIGNALING_UP0.350Inavolisib— uncovered
PANCREAS_BETA_CELLS0.280Cobimetinib— uncovered
APOPTOSIS0.220Idelalisib— uncovered
ANGIOGENESIS0.210Remibrutinib— uncovered
XENOBIOTIC_METABOLISM0.200Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.190Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.140Inavolisib— uncovered
APICAL_SURFACE0.120Temsirolimus— uncovered
APICAL_JUNCTION0.110Inavolisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.090Idelalisib— uncovered